IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IceCure Medical (Nasdaq: ICCM), a developer of minimally-invasive cryoablation technology for tumor treatment, will release its Q3 2024 financial and operational results before Nasdaq market opening on November 26, 2024. The company will host a conference call and webcast at 10:00 AM EST the same day to discuss the results and corporate developments. The call will be accessible via US toll-free and international dial-in numbers, with a live webcast available through the company's website.
Details
News Market Reaction – ICCM
The recorded move for ICCM in the trading session of this news was -1.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.

Conference call & webcast info:
Tuesday, November 26, 2024, at 10:00 am EST
US: 1-888-407-2553
A live webcast will be available at: https://Veidan.activetrail.biz/IcecureQ3-2024
A recording of the webcast will be available at: ir.icecure-medical.com/
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses its expected announcement of financial and operational results as of and for the nine months ended September 30, 2024 and hosting a conference call related to such results. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo - https://mma.prnewswire.com/media/2319310/4496307/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-third-quarter-2024-financial--operational-results-on-november-26-2024-302311232.html
SOURCE IceCure Medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.